Study of IPM514 for esophageal squamous cell carcinoma
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational drug called IPM514 in people with esophageal squamous cell carcinoma that has progressed after prior treatments. The goal is to see if IPM514 can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with esophageal squamous cell carcinoma.
- You have already tried a PD-1/PD-L1 inhibitor (like pembrolizumab or nivolumab) and a platinum-based chemotherapy, and the cancer has grown despite these treatments.
- You have a specific genetic marker called HLA-A*02:01 or HLA-A*11:01 (a blood test can check this).
- You are generally well enough to carry out daily activities (ECOG performance status 0 or 1).
- Your organ function (kidney, liver, blood counts) is within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study tests a new treatment for people with locally advanced esophageal cancer that did not respond to initial chemotherapy and immunotherapy. The goal is to see if the study drug can shrink or control the cancer when surgery is not an option.
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.